Advanced Contrast-Enhanced MRI for Stroke Risk Assessment
description
Transcript of Advanced Contrast-Enhanced MRI for Stroke Risk Assessment
![Page 1: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/1.jpg)
Advanced Contrast-Enhanced MRI for Stroke Risk Assessment
Bruce Wasserman, M.D.Director of Diagnostic Neurovascular ImagingJohns Hopkins Medical Institutions
![Page 2: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/2.jpg)
Gadolinium-enhanced MR Imaging
Objectives• Identifying Vulnerable Plaque (Carotid)
– Anatomic Features– Inflammation
• Extend to intracranial vessels
![Page 3: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/3.jpg)
Identifying Vulnerable Plaque
LumenLipidCore
Fibrous Cap Rupture
Plaque Rupture
![Page 4: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/4.jpg)
LumenLipidCore
Clot
Thin capLarge core
Fibrous Cap Rupture
Plaque Rupture
Identifying Vulnerable Plaque
![Page 5: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/5.jpg)
PlaqueLumen
Black Blood MRI
![Page 6: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/6.jpg)
• Gadolinium-enhanced Black Blood MRI (CEMRI)
Core
Pre - contrast MRI
Black Blood MRI
PlaqueLumen
Post
–Enhancement of fibrous tissue improves delineation of lipid core
![Page 7: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/7.jpg)
CalciumLumen
Fibrocellulartissue
Lipidcore
H&E
Wasserman et al. Radiology 2002
Precontrast PostcontrastEndarterectomy Specimen
(Gadolinium–DPTA)
![Page 8: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/8.jpg)
Technical Considerations
• Dedicated neck coil• 3T
– 250µ in-plane resolution• Delayed images
– 5 minutes after contrast administration
• 1.5T – 500µ in-plane resolution
– Acquire CE-MRA during injection
![Page 9: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/9.jpg)
ICA
ECA
CCAEndarterectomy
specimen
CEMRA-Mask ImageMRA
Contrast-Enhanced MRA (MASK images)
Qiao, Etesami, Malhotra, Astor, Virmani, Kolodgie, Trout, Wasserman. AJRN March, 2010
Red-staining IPH
![Page 10: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/10.jpg)
ICA
ECA
CCAEndarterectomy
specimen
CEMRA-Mask ImageMRA
Contrast-Enhanced MRA (MASK images)
Qiao, Etesami, Malhotra, Astor, Virmani, Kolodgie, Trout, Wasserman. AJRN March, 2010
Sensitivity Specificity PPV NPV Accuracy 87% 99% 98% 91% 94%
Intra- observer agreement: κ =0.94 (95% CI: 0.87-1.0)Inter-observer agreement: κ =0.91 (95% CI: 0.84-0.98)
Intraplaque Hemorrhage ( )IPH Detection
Red-staining IPH
![Page 11: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/11.jpg)
• Indicates risk for prior plaque rupture1,2
• Indicates risk for future embolic events3-6
IPH DetectionIntraplaque Hemorrhage ( )
1Chu et al. Stroke 2004;35:1079-10842Takaya et al. Circulation 2005;111:2768-27753Altaf et al. J Vasc Surg 2008;47:337-3424Altaf et al. J Vasc Surg 2007;46:31-365Singh et al. Radiology 2009;252:502-5086Takaya et al. Stroke 2006;37:818-823
![Page 12: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/12.jpg)
61 year old male with 2 year history of left hemisphere strokes
Left Carotid MRA
Wasserman et al. Stroke. 2005 Nov;36(11):2504-13.
![Page 13: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/13.jpg)
January 13, 2003
November 5, 2003
October 2003 stroke
Wasserman et al. Stroke. 2005 Nov;36(11):2504-13.
![Page 14: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/14.jpg)
November 5, 2003
T1 Precontrast T1 Postcontrast
Wasserman et al. Stroke. 2005 Nov;36(11):2504-13.
![Page 15: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/15.jpg)
November 5, 2003
T1 Precontrast T1 Postcontrast
Wasserman et al. Stroke. 2005 Nov;36(11):2504-13.
![Page 16: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/16.jpg)
SiriusRed
T1 Postcontrast
November 5, 2003
Before After
Wasserman et al. Stroke. 2005 Nov;36(11):2504-13.
![Page 17: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/17.jpg)
Neovascularization
• Neovascularity Symptomatic, ruptured plaques1-5
• Neovascularity Intraplaque hemorrhage1
– IPH stimulates plaque progression6
1Virmani. ATVB 2005;25:2054-612Moreno. Circ 2004;110:2032-83Jeziorska. J Pathol 1999;188:189-1964Fleiner. Circ 2004;110:2843-28505Russell. Br J Surg 2008;95:576-5816Takaya. Circ 2005;111:2768-2775
![Page 18: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/18.jpg)
Contrast-enhancement
Neovessels in Adventitia
Reader 1
0 1 2 Total
Reader 2
0 5 4 0 9
1 1 17 7 25
2 0 3 21 24
Total 6 24 28 58
Category 0: No enhancementCategory 1: < 50% enhancementCategory 2: ≥ 50% enhancement
(Average adventitial enhancement for 5 adjacent slices)Weighted κ =0.81 (95% CI: 0.68-0.89)
5 4 0 9
1 17 7 25
0 3 21 24
6 24 28 58Precontrast Postcontrast
ICA LumenICA Lumen
Postcontrast Black Blood MRI Images:
Wasserman BA. Stroke October, 2010
![Page 19: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/19.jpg)
P=0.003
Association of IPH with recent ipsilateral Stroke/TIA
P=0.001
58 consecutive contrast-enhanced black blood MRI exams for carotid stenosis
2 Readers blinded to clinical information
Association of Adventitial Enhancement with recent ipsilateral Stroke/TIA
45 males, 13 females; Mean age 73 years (49 – 89 years)31 (53%) had recent ipsilateral stroke/TIA32 (55%) had IPH
Median stenosis = 65%
IPH absent IPH present0%
20%
40%
60%
80%
100%
% o
f cas
es w
ith st
roke
/TIA
IPH absent IPH present
% o
f cas
es w
ith st
roke
/TIA
adventitial enhancement
adventitial enhancement
0%
20%
40%
60%
80%
100%
0
1
2
Adventitial Enhancement
AE Category
(Neovascularity)
Wasserman BA. Stroke October, 2010
0 1 2
![Page 20: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/20.jpg)
Association of Adventitial Enhancement (AE) and IPH with Stroke/TIA
Wasserman BA. Stroke October, 2010
2 Readersadventitial enhancement adventitial enhancement0%
20%
40%
60%
80%
100%
012
AE Category
IPH absent IPH present
% o
f cas
es w
ith st
roke
/TIA
Adventitial Enhancement0 1 2
Adventitial Enhancement0 1 2
![Page 21: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/21.jpg)
Association of Adventitial Enhancement (AE) and IPH with Stroke/TIA
ORs 95% CIAge (years) 0.97 0.89 – 1.06
Female 0.18 0.02 – 1.42
Active smoker 2.15 0.22 – 21.00
HTN 0.35 0.06 – 2.15
DM 3.58 0.66 – 19.36
Hyperlipidemia 0.51 0.06 – 4.09
Statin use 3.41 0.39 – 30.13
ASA use 0.88 0.09 – 8.76
Wall thickness (mm) 1.62 0.61 – 4.30
AE (Category 1 vs 0) 11.82 2.48 – 56.30
AE (Category 2 vs 0) 58.13 10.12 – 333.87
IPH (present vs absent) 5.90 1.09 – 31.86
Stenosis (continuous) 0.09 0.01 – 4.54
Wasserman BA. Stroke October, 2010
Odds Ratios for Recent Stroke/TIA:
2 Readersadventitial enhancement adventitial enhancement0%
20%
40%
60%
80%
100%
012
AE Category
IPH absent IPH present
% o
f cas
es w
ith st
roke
/TIA
Adventitial Enhancement0 1 2
Adventitial Enhancement0 1 2
![Page 22: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/22.jpg)
Association of Adventitial Enhancement (AE) and IPH with Stroke/TIA
ORs 95% CIAge (years) 0.97 0.89 – 1.06
Female 0.18 0.02 – 1.42
Active smoker 2.15 0.22 – 21.00
HTN 0.35 0.06 – 2.15
DM 3.58 0.66 – 19.36
Hyperlipidemia 0.51 0.06 – 4.09
Statin use 3.41 0.39 – 30.13
ASA use 0.88 0.09 – 8.76
Wall thickness (mm) 1.62 0.61 – 4.30
AE (Category 1 vs 0) 11.82 2.48 – 56.30
AE (Category 2 vs 0) 58.13 10.12 – 333.87
IPH (present vs absent) 5.90 1.09 – 31.86
Stenosis (continuous) 0.09 0.01 – 4.54
Wasserman BA. Stroke October, 2010
Odds Ratios for Recent Stroke/TIA:
![Page 23: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/23.jpg)
Association of Adventitial Enhancement (AE) and IPH with Stroke/TIA
ORs 95% CIAge (years) 0.97 0.89 – 1.06
Female 0.18 0.02 – 1.42
Active smoker 2.15 0.22 – 21.00
HTN 0.35 0.06 – 2.15
DM 3.58 0.66 – 19.36
Hyperlipidemia 0.51 0.06 – 4.09
Statin use 3.41 0.39 – 30.13
ASA use 0.88 0.09 – 8.76
Wall thickness (mm) 1.62 0.61 – 4.30
AE (Category 1 vs 0) 11.82 2.48 – 56.30
AE (Category 2 vs 0) 58.13 10.12 – 333.87
IPH (present vs absent) 5.90 1.09 – 31.86
Stenosis (continuous) 0.09 0.01 – 4.54
Wasserman BA. Stroke October, 2010
Odds Ratios for Recent Stroke/TIA:
![Page 24: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/24.jpg)
Intracranial CE-MRI
Swartz RH, et al. Intracranial Arterial Wall Imaging Using High Resolution 3-Tesla Contrast-enhanced MRI. Neurology 2009;72(7):627-634.
T2 FRFSE T1 FLAIR Precontrast T1 FLAIR Postcontrast
![Page 25: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/25.jpg)
• 13 patients with intracranial atherosclerosis and recent TIA or stroke– 12 had focal eccentric wall enhancement of
intracranial vessel supplying territory of acute infarct– Plaques in MCA, ACA, Basilar arteries– 10 of 12 had enhancement only in vessel supplying
area of acute infarct even when multiple plaques
Swartz RH, et al. Intracranial Arterial Wall Imaging Using High Resolution 3-Tesla Contrast-enhanced MRI. Neurology 2009;72(7):627-634.
Intracranial CE-MRI
![Page 26: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/26.jpg)
Swartz RH, et al. Intracranial Arterial Wall Imaging Using High Resolution 3-Tesla Contrast-enhanced MRI. Neurology 2009;72(7):627-634.
Intracranial CE-MRI
T1 FLAIR Precontrast T1 FLAIR Postcontrast
![Page 27: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/27.jpg)
64 yo male with blurred vision, dizziness and dysarthria
May 27, 2007
![Page 28: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/28.jpg)
May 27, 2007June 1, 2007
![Page 29: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/29.jpg)
June 1, 2007
![Page 30: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/30.jpg)
June 1, 2007 Sept 18, 2007(3 months of statin use)Time
![Page 31: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/31.jpg)
Sept 18, 2007
June 1, 2007 Sept 18, 2007
Time
![Page 32: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/32.jpg)
June 1, 2007 Sept 18, 2007
June 1, 2007 Sept 18, 2007
Time
![Page 33: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/33.jpg)
June 1, 2007 Sept 18, 2007
Sept 18, 2007 Feb 06, 2008
Feb 06, 2008
Time
![Page 34: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/34.jpg)
Sept 18, 2007 Feb 06, 2008
Feb 06, 2008Sept 18, 2007 Feb 06, 2008Time
![Page 35: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/35.jpg)
Summary
Contrast-enhanced Plaque MRI:• Black blood images pre- and post-contrast
– Fibrous cap thickness, lipid core size, calcification– Adventitial enhancement score (i.e., neovascularity)
• CEMRA during arterial phase– Mask image - IPH
![Page 36: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/36.jpg)
Summary
Contrast-enhanced Plaque MRI:Determine plaque vulnerability
Identify the culprit lesionMonitor therapeutic response
![Page 37: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/37.jpg)
Acknowledgments• Ye Qiao, PhD• Maryam Etesami, MD• Brad Astor, PhD• Matthias Stuber, PhD• Steven R. Zeiler, MD, PhD• Robert Wityk, MD• Victor Urrutia, MD• Hugh H. Trout, III, MD• Frank Kolodgie, PhD• Renu Virmani, MD
![Page 38: Advanced Contrast-Enhanced MRI for Stroke Risk Assessment](https://reader036.fdocuments.net/reader036/viewer/2022062501/56816183550346895dd1176f/html5/thumbnails/38.jpg)